In this prospective study of 57 patients with multiple myeloma, 26 underwent allogeneic HCT for consolidation after a response to their first autologous transplant, and 30 patients received an allogeneic HCT as salvage therapy. At a median follow up of 52 months, 32 (57.1%) patients achieved a complete response (CR), and at five years, 49.2% of all patients were in CR. Five-year overall survival (OS) for all patients was 59%. For the 30 patients in the consolidation group, OS was 82% compared with 38% for those in the salvage group (p=0.0005). In an accompanying editorial, Dr. Paul Richardson noted that these results provide “important information to challenge a strongly held view in the field of myeloma that there is little or no role for allo-HCT.”
Donato ML, et al. Biol Blood Marrow Transplant